Status:
COMPLETED
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Burkitt's Lymphoma
Burkitt'S-like Lymphoma
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
The goal of this clinical research study is to learn if intensive chemotherapy given over 6 months can help to control or cure Burkitt's leukemia, Burkitt's lymphoma, or small non-cleaved cell B-cell ...
Detailed Description
The hyper-CVAD regimen is a combination of chemotherapy drugs including cyclophosphamide, vincristine, Adriamycin, and dexamethasone given together to for one "course" of treatment. This alternates wi...
Eligibility Criteria
Inclusion
- Burkitt's or Burkitt-like leukemia and/or lymphoma, either previously untreated, previously treated (may be in CR or with active disease after 1-2 courses of chemotherapy), or HIV-related.
- All ages are eligible.
- Zubrod performance status \< 3 (ECOG Scale, Appendix A).
- Adequate liver function (bilirubin \< 3.0 mg/dL, unless considered due to tumor), and renal function (creatinine \< 3.0 mg/dL, unless considered due to tumor).
- Signed informed consent.
Exclusion
- 1\) N/A
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00669877
Start Date
August 1 2002
End Date
October 1 2015
Last Update
May 16 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States, 77030